OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
BDMD$1.6955

Baird Medical Investment Holdings Ltd

Medical Equipment, Supplies & DistributionVerified

The company's capital structure shows a debt-to-equity ratio of 0.61, indicating a moderate level of leverage. However, the liquidity position is concerning, with negative net cash after subtracting total debt. The price-to-book ratio of 2.19 suggests the market is valuing the company at a premium to its book value, but the negative return on equity of -0.8696 and return on assets of -0.3914 highlight significant underperformance relative to its capital base. Profitability metrics are severely underperforming compared to industry norms. The company reported a net loss of $27.28 million, with an operating loss of $25.63 million. Gross profit of $18.88 million is insufficient to cover operating expenses, leading to a negative return on equity and assets. These metrics indicate a company struggling to generate sustainable earnings and efficiently utilize its assets. Geographic and segment exposure data is not available in the provided input, but the company's revenue concentration and segment performance are critical to assess. The absence of detailed segment data limits the ability to evaluate diversification and growth drivers within the business. The company's growth trajectory is negative, with a net loss in the most recent period. The outlook for the current fiscal year is not provided, but the negative operating and free cash flows suggest a challenging path to profitability. The company's ability to reverse these trends will depend on cost management, revenue growth, and operational efficiency improvements. Risk factors include liquidity constraints, with negative net cash and a current ratio of 1.7, indicating potential short-term liquidity pressures. The risk assessment flags net cash as negative after subtracting total debt, and the company has a low dilution risk. However, the negative operating and free cash flows suggest a need for careful capital management to avoid further dilution or financial distress. Recent events and filings are not detailed in the input, but the company's financial performance and risk profile suggest a need for close monitoring of its capital structure and operational improvements. The absence of recent positive developments or strategic initiatives in the input data indicates a lack of immediate catalysts for recovery.

30-day price · BDMD-0.27 (-13.4%)
Low$1.59High$2.16Close$1.75As of10 May, 00:00 UTC
Profile
CompanyBaird Medical Investment Holdings Ltd
TickerBDMD.O
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. Baird Medical Investment Holdings Ltd operates in the medical equipment, supplies, and distribution industry, providing healthcare services and equipment to its clients.

Classification. The company is classified under the Healthcare Services & Equipment business sector within the Healthcare economic sector, with a classification confidence of 0.92.

The company's capital structure shows a debt-to-equity ratio of 0.61, indicating a moderate level of leverage. However, the liquidity position is concerning, with negative net cash after subtracting total debt. The price-to-book ratio of 2.19 suggests the market is valuing the company at a premium to its book value, but the negative return on equity of -0.8696 and return on assets of -0.3914 highlight significant underperformance relative to its capital base. Profitability metrics are severely underperforming compared to industry norms. The company reported a net loss of $27.28 million, with an operating loss of $25.63 million. Gross profit of $18.88 million is insufficient to cover operating expenses, leading to a negative return on equity and assets. These metrics indicate a company struggling to generate sustainable earnings and efficiently utilize its assets. Geographic and segment exposure data is not available in the provided input, but the company's revenue concentration and segment performance are critical to assess. The absence of detailed segment data limits the ability to evaluate diversification and growth drivers within the business. The company's growth trajectory is negative, with a net loss in the most recent period. The outlook for the current fiscal year is not provided, but the negative operating and free cash flows suggest a challenging path to profitability. The company's ability to reverse these trends will depend on cost management, revenue growth, and operational efficiency improvements. Risk factors include liquidity constraints, with negative net cash and a current ratio of 1.7, indicating potential short-term liquidity pressures. The risk assessment flags net cash as negative after subtracting total debt, and the company has a low dilution risk. However, the negative operating and free cash flows suggest a need for careful capital management to avoid further dilution or financial distress. Recent events and filings are not detailed in the input, but the company's financial performance and risk profile suggest a need for close monitoring of its capital structure and operational improvements. The absence of recent positive developments or strategic initiatives in the input data indicates a lack of immediate catalysts for recovery.
Key takeaways
  • The company is operating at a significant loss, with negative returns on equity and assets.
  • Liquidity is a concern, with negative net cash after subtracting total debt.
  • The price-to-book ratio is high, but the company's fundamentals do not support this valuation.
  • The company's growth trajectory is negative, and profitability is underperforming.
  • Risk factors include liquidity constraints and the need for operational improvements.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$22.5M
Gross profit$18.9M
Operating income-$25.6M
Net income-$27.3M
R&D
SG&A
D&A
SBC
Operating cash flow-$1.3M
CapEx-$42.3k
Free cash flow-$26.5M
Total assets$69.7M
Total liabilities$38.3M
Total equity$31.4M
Cash & equivalents$178.3k
Long-term debt$19.2M
Valuation
Market price$1.69
Market cap$68.8M
Enterprise value$87.7M
P/E
Reported non-GAAP P/E
EV/Revenue3.9
EV/Op income
EV/OCF
P/B2.2
P/Tangible book2.2
Tangible book$31.4M
Net cash-$19.0M
Current ratio1.7
Debt/Equity0.6
ROA-39.1%
ROE-87.0%
Cash conversion5.0%
CapEx/Revenue-0.2%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 369 companies
MetricBDMDActivity
Op margin-113.7%3.9% medp25 -31.3% · p75 14.4%bottom quartile
Net margin-121.0%2.4% medp25 -30.5% · p75 11.1%bottom quartile
Gross margin83.8%46.7% medp25 28.2% · p75 63.1%top quartile
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-0.2%-4.8% medp25 -11.6% · p75 -2.4%top quartile
Debt / equity61.0%17.9% medp25 2.7% · p75 52.2%top quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-16 15:36 UTC#041aafea
Market quoteclose USD 1.86 · shares 0.04B diluted
no public URL
2026-05-16 15:38 UTC#618e0a73
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 11:33 UTCJob: cf47e431